查詢結果分析
相關文獻
- 懷孕使用SSRIs安全性之初探
- Lung Cancer in Pregnancy: Report of Two Cases
- Lactation Promotes the Normalization of Plasma Lipids and Lipoproteins after Delivery in Taiwanese Women
- Spontaneous Uterine Rupture during Pregnancy
- 懷孕週數與低出生體重及極低出生體重嬰兒盛行率之研究
- 未去勢雄性肉豬含男性脂酮和糞臭素含量影響豬肉腥臭味以及懷孕母豬飼料含葉酸對於繁殖表現之研究報導
- 孕期性生活之文獻探討
- 婦女流產及死胎後之心身適應
- 黃體素應用於懷孕時會引起胎兒畸形嗎?
- 懷孕早期孕婦血清的唐氏症篩檢
頁籤選單縮合
| 題 名 | 懷孕使用SSRIs安全性之初探=Preliminiary the Safety of SSRIs during Pregnancy |
|---|---|
| 作 者 | 盧志魁; 林佳慧; 陳琦華; 陳惠玉; | 書刊名 | 藥學雜誌 |
| 卷 期 | 33:1=130 2017.03[民106.03] |
| 頁 次 | 頁94-100 |
| 分類號 | 418.214 |
| 關鍵詞 | 選擇性血清素再回收抑制劑; 懷孕; SSRIs; Pregnancy; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | SSRIs (selective serotonin reuptake inhibitor) 由於其較高的安全性,是憂鬱症的首 選治療藥品,其在懷孕時的使用率約3-10%1,2。處於疾病穩定狀態下並持續用藥的憂 鬱症患者,當懷孕時考慮停藥的同時必須警覺憂鬱症復發的風險。目前大部分的證據 評估結果不容易區分是因母親的憂鬱症或是孕期使用 SSRIs 所造成的安全性影響。憂 鬱症婦女懷孕時為了防止母嬰併發症的發生、為避免憂鬱症復發及維護良好的母嬰關 係,臨床鼓勵孕期還是應接受治療,若需要藥品治療首選建議為 SSRIs,並且須定期 評估母親疾病控制及胎兒成長發育情況,期在利益和風險之間取得最佳的平衡。 |
| 英文摘要 | Selective serotonin reuptake inhibitors (SSRIs), due to their favorable safety profile, are the first-line pharmacotherapy of depression. The utilization of SSRIs during pregnancy is about 3-10%. While depressed symptoms are stable under treatment, pregnant patients who consider discontinuing SSRIs must also take into account of the risk of depression recurrence. Currently, between the risk of maternal depression versus the risk of continuing SSRIs during pregnancy, most of the evidence do not clearly indicate if one outweighs another. In order to prevent maternal complications during pregnancy and maintain healthy maternal-infant relationship, it is encouraged to continue to receive treatment for depression. SSRIs will be the first-line recommendations if a pharmacotherapy is chosen. Regular assessment of depression management and fetal growth and development will be needed in order to achieve the optimal balance between benefits and risks. |
本系統中英文摘要資訊取自各篇刊載內容。